Morgan Stanley Increases Envista (NYSE:NVST) Price Target to $21.00

Envista (NYSE:NVST) had its price target increased by analysts at Morgan Stanley from $19.00 to $21.00 in a report issued on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s target price would suggest a potential downside of 22.40% from the company’s current price.

Several other research analysts have also recently commented on the stock. Weiss Ratings raised shares of Envista from a “sell (d)” rating to a “hold (c-)” rating in a report on Tuesday, February 17th. Evercore set a $30.00 price objective on Envista in a research note on Wednesday, April 8th. Citigroup initiated coverage on Envista in a report on Wednesday, April 15th. They issued a “neutral” rating and a $29.00 price objective for the company. William Blair raised Envista from a “hold” rating to an “outperform” rating in a report on Friday, February 6th. Finally, UBS Group raised their price target on Envista from $22.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, Envista presently has an average rating of “Hold” and an average price target of $27.85.

Envista Stock Down 0.3%

Envista stock opened at $27.06 on Friday. The stock has a market cap of $4.41 billion, a P/E ratio of 96.65, a P/E/G ratio of 1.85 and a beta of 0.98. The company has a quick ratio of 2.04, a current ratio of 2.38 and a debt-to-equity ratio of 0.47. Envista has a twelve month low of $15.49 and a twelve month high of $30.42. The company’s 50-day moving average price is $26.95 and its two-hundred day moving average price is $23.65.

Envista (NYSE:NVST) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of $0.32 by $0.06. Envista had a net margin of 1.73% and a return on equity of 6.54%. During the same period in the prior year, the firm earned $0.24 EPS. Envista’s quarterly revenue was up 15.0% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. As a group, analysts expect that Envista will post 1.4 EPS for the current year.

Insider Transactions at Envista

In related news, SVP Mischa Reis sold 9,675 shares of the stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $30.00, for a total value of $290,250.00. Following the completion of the transaction, the senior vice president owned 32,382 shares of the company’s stock, valued at $971,460. This represents a 23.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.99% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NVST. Millennium Management LLC lifted its stake in shares of Envista by 1,442.7% in the 4th quarter. Millennium Management LLC now owns 2,420,615 shares of the company’s stock valued at $52,552,000 after acquiring an additional 2,263,712 shares during the last quarter. Holocene Advisors LP acquired a new stake in shares of Envista during the 2nd quarter valued at $43,936,000. Norges Bank bought a new stake in Envista during the 4th quarter worth $45,113,000. Alliancebernstein L.P. grew its position in Envista by 34.0% during the 2nd quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock worth $119,164,000 after acquiring an additional 1,547,656 shares during the last quarter. Finally, Freestone Grove Partners LP acquired a new position in Envista in the 4th quarter worth about $29,046,000.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.